Peripheral Neuropathy Trial, Recruiting (NCT04561518)

Peripheral Neuropathy Trial, Recruiting NCT04561518 Sponsor: Alnylam Pharmaceuticals Condition: Peripheral Neuropathy

Printed from Voxsanity (voxsanity.com.au) — NCT04561518 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Peripheral Neuropathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with ATTR amyloidosis, or who carry a known gene variant that causes ATTR amyloidosis but do not yet have symptoms
(Germany only) People who are currently receiving an approved treatment for ATTR amyloidosis, used in the way that treatment is officially approved to be used

Who may not be able to join:

People who are currently enrolled in another clinical trial testing an investigational (not yet fully approved) treatment

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Medical Director, Alnylam Pharmaceuticals

Phone: 1-877-ALNYLAM

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04561518

Sponsor: Alnylam Pharmaceuticals

Phase: Not Applicable

Status: Recruiting

Condition: Peripheral Neuropathy

Trial contact: 1-877-ALNYLAM

More information: https://clinicaltrials.gov/study/NCT04561518

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with ATTR amyloidosis, or who carry a known gene variant that causes ATTR amyloidosis but do not yet have symptoms
(Germany only) People who are currently receiving an approved treatment for ATTR amyloidosis, used in the way that treatment is officially approved to be used

Who may not be able to join:

People who are currently enrolled in another clinical trial testing an investigational (not yet fully approved) treatment

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Alnylam Pharmaceuticals

Registry

ClinicalTrials.gov

Start date

23 November 2020

Est. completion

31 December 2033

Where this trial is recruiting

🇧🇷 Brazil 🇧🇬 Bulgaria 🇩🇰 Denmark 🇫🇷 France 🇩🇪 Germany 🇮🇱 Israel 🇮🇹 Italy 🇳🇱 Netherlands 🇵🇹 Portugal 🇪🇸 Spain 🇹🇼 Taiwan 🇺🇸 United States

Primary endpoints

Incidence of Adverse Events; Selected Events of Interest in Patients with Hereditary Transthyretin-mediated (hATTR) or Wild-type Transthyretin-mediated (wtATTR) Amyloidosis (ATTRv Amyloidosis); Health Care Provider (HCP)-Assessed Polyneuropathy (PND) Disability Score; HCP-Assessed Familial Amyloidotic Polyneuropathy (FAP) Score; HCP-Assessed Neuropathy Impairment Score (NIS); HCP-Assessed Cardiomyopathy; HCP- Assessed Cardiopulmonary Exercise Testing (CPET) Performance; Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Total Score; Kansas City Cardiomyopathy Questionnaire (KCCQ); Rasch-bu...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov